0.6939USD-0.87%Mkt Cap: 22.99M USDP/E: —Last update: 2026-05-26
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead produc…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap22.99M USD
Enterprise Value-32.42M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-20.43M USD
Revenue/Share—
Last Price0.6939 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.71
PEG—
EV/EBITDA1.88
EV/Revenue—
P/S—
P/B0.33
EPS (TTM)-1.42
EPS (Forward)-1.01
52W Range
0.281023% of range2.060
52W High2.060 USD
52W Low0.2810 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-36.99%
ROA-33.91%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.21M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-51.66%
Net Debt-50.40M USD
Net Debt/EBITDA2.92
Balance Sheet
Debt/Equity—
Current Ratio35.40
Quick Ratio33.84
Book Value/Sh2.198 USD
Cash/Share2.021 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJan 2, 2024
Analyst Consensus
Rating—
Target (Mean)3.000 USD
Target Range3.000 USD – 3.000 USD
# Analysts1
Ownership
Shares Out.33.41M
Float10.20M
Insiders1.11%
Institutions60.04%
Short Interest
Short Ratio0.3d
Short % Float1.09%
Short % Out.1.07%
Shares Short267.04K
Short (prev mo.)122.49K
Technical
SMA 500.7638 (-9.2%)
SMA 2000.8167 (-15.0%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)376.50K
Avg Vol (10d)214.72K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—